



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.: C1041/7002

SERIAL NO.: 09/241,653

APPLICANT: Wagner et al.

FILING DATE: February 2, 1999

GROUP: 1635

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS

	Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
83	WO 96/05553	02/01/96	PCT International	C07H	21/00	
	WO 97/28259	08/07/97	PCT International	C12N	15/00	
	WO 98/11211	03/19/98	PCT International	C12N	15/11	
	WO 98/10810	05/07/98	PCT International	C07H	21/00	

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

83		Agrawal S et al., Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. <i>Antisense Nucleic Acid Drug Dev</i> 1997; 7:575-84.
		International Search Report, mailed from the EPO on March 12, 1999
93		Jakob et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. <i>Int Arch Allergy Immunol</i> 1999; 118(2-4):457-61.
		Krieg AM et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge. <i>J Immunol</i> 1998; 161(5):2428-34.
		Lipford GB et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol</i> 1997; 27:3420-6.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER

DATE CONSIDERED

9/16/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.